Lundbeck Pharms Llc Drug Patent Portfolio
Lundbeck Pharms Llc owns 1 orange book drug protected by 7 US patents Given below is the list of Lundbeck Pharms Llc's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11529357 | Injectable carbamazepine composition essentially free of 10-bromo-carbamazepine | 31 Jan, 2040 | Active |
| US9493582 | Alkylated cyclodextrin compositions and processes for preparing and using the same | 27 Feb, 2033 | Active |
| US7635773 | Sulfoalkyl ether cyclodextrin compositions | 13 Mar, 2029 | Active |
| US8410077 | Sulfoalkyl ether cyclodextrin compositions | 13 Mar, 2029 | Active |
| US9750822 | Sulfoalkyl ether cyclodextrin compositions | 13 Mar, 2029 | Active |
| US9629797 | Parenteral carbamazepine formulation | 10 Nov, 2028 | Active |
| US9770407 | Parenteral carbamazepine formulation | 10 Nov, 2028 | Active |
Latest Legal Activities on Lundbeck Pharms Llc's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Lundbeck Pharms Llc.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 8th Year, Large Entity | 30 Apr, 2024 | US9493582 |
| Post Issue Communication - Certificate of Correction | 08 Feb, 2023 | US11529357 |
|
Recordation of Patent Grant Mailed
Critical
| 20 Dec, 2022 | US11529357 |
|
Patent Issue Date Used in PTA Calculation
Critical
| 20 Dec, 2022 | US11529357 |
|
Correspondence Address Change
Critical
| 04 Dec, 2022 | US9750822 |
|
Correspondence Address Change
Critical
| 04 Dec, 2022 | US8410077 |
|
Correspondence Address Change
Critical
| 04 Dec, 2022 | US9493582 |
|
Correspondence Address Change
Critical
| 04 Dec, 2022 | US7635773 |
|
Email Notification
Critical
| 01 Dec, 2022 | US11529357 |
|
Issue Notification Mailed
Critical
| 30 Nov, 2022 | US11529357 |
|
Application Is Considered Ready for Issue
Critical
| 16 Nov, 2022 | US11529357 |
| Dispatch to FDC | 16 Nov, 2022 | US11529357 |
|
Issue Fee Payment Received
Critical
| 14 Nov, 2022 | US11529357 |
|
Issue Fee Payment Verified
Critical
| 14 Nov, 2022 | US11529357 |
|
Electronic Review
Critical
| 21 Oct, 2022 | US11529357 |
Lundbeck Pharms Llc's Drug Patent Litigations
Lundbeck Pharms Llc's drugs have been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Jul 03, 2014, against patent number US9629797. The petitioner , challenged the validity of this patent, with James Cloyd et al as the respondent. Click below to track the latest information on how companies are challenging Lundbeck Pharms Llc's patents.
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
 | ||||
| US9770407 | December, 2014 |
Decision
(15 Mar, 2017)
| Lundbeck Pharmaceuticals LLC | |
| US9629797 | July, 2014 |
Decision
(15 Dec, 2016)
| James Cloyd et al | |
Lundbeck Pharms Llc Drug Patents' Oppositions Filed in EPO
Lundbeck Pharms Llc drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Feb 06, 2015, by Actavis Group Ptc Ehf. This opposition was filed on patent number EP06816054A. Click below to reveal the latest opposition data.
| Application | Filing Date | Opposition Party | Legal Status |
|---|---|---|---|
| | |||
| EP06816054A | Feb, 2015 | Actavis Group PTC ehf | Revoked |
Lundbeck Pharms Llc's Family Patents
Lundbeck Pharms Llc Drug List
Given below is the complete list of Lundbeck Pharms Llc's drugs and the patents protecting them.
1. Carnexiv
Carnexiv is protected by 7 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11529357 | Injectable carbamazepine composition essentially free of 10-bromo-carbamazepine |
31 Jan, 2040
(14 years from now)
| Active |
| US9493582 | Alkylated cyclodextrin compositions and processes for preparing and using the same |
27 Feb, 2033
(7 years from now)
| Active |
| US7635773 | Sulfoalkyl ether cyclodextrin compositions |
13 Mar, 2029
(3 years from now)
| Active |
| US8410077 | Sulfoalkyl ether cyclodextrin compositions |
13 Mar, 2029
(3 years from now)
| Active |
| US9750822 | Sulfoalkyl ether cyclodextrin compositions |
13 Mar, 2029
(3 years from now)
| Active |
| US9629797 | Parenteral carbamazepine formulation |
10 Nov, 2028
(3 years from now)
| Active |
| US9770407 | Parenteral carbamazepine formulation |
10 Nov, 2028
(3 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Carnexiv's drug page